Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at greenstockmovers.com, will continue to monitor these healthtech companies to see if the momentum continues. GreenStockMovers.com is also looking into these tickers COP, MTDR, PXD and more..
Recent REGN Stock Price: $820.41
Summary: Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also developed an antibody cocktail for COVID-19, REGEN-COV. REGEN-COV is a cocktail of two monoclonal antibodies and was designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron has a collaboration agreement with Roche for the same. While Regeneron has co-developed Eylea with Bayer's HealthCare unit, Praluent was co-developed with Sanofi. Regeneron collaborated with Bayer for the joint development and commercialization of co-formulated combinations of Eylea, rinucumab and nesvacumab for the treatment of ocular diseases or disorders outside the United States.
David Risinger analyst at SVB Securities reiterates coverage on Regeneron (REGN) stock in the energy sector with a Buy rating and has set REGN's stock price target at $ 976.
TipRanks.com reports that Regeneron currently has 18 analysts offering 12-month price targets on REGN and the consensus is a Moderate Buy rating with an average stock price target of $877.88. The most recent REGN stock price we have is $820.41 and we are not making any REGN forecasts at this time.
In addition, TradingView issued a Buy rating for REGN over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on REGN. greenstockmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on REGN, please click here >>
89bio, ETNB
Recent ETNB Stock Price: $16.35
Summary: 89bio Inc. is clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is being developed for the treatment of nonalcoholic steatohepatitis. 89bio Inc. is headquartered in San Francisco.
Geoff Meacham analyst at Bank of America Securities reiterates coverage on 89bio (ETNB) stock in the energy sector with a Buy rating and has set ETNB's stock price target at $ 24.
TipRanks.com reports that 89bio currently has 8 analysts offering 12-month price targets on ETNB and the consensus is a Strong Buy rating with an average stock price target of $34.63. The most recent ETNB stock price we have is $16.35 and we are not making any ETNB forecasts at this time.
In addition, TradingView issued a Buy rating for ETNB over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ETNB. greenstockmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ETNB, please click here >>
Sanofi, SNYNF
Recent SNYNF Stock Price: $107.05
Summary: Sanofi was incorporated under the laws of France in 1994 as a société anonyme, a form of limited liability company. It is a healthcare company, engaged in the research, development, manufacture and marketing of healthcare products. Its principal activities include Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. It also operates through the following platforms: Emerging Markets, Diabetes Solutions, Vaccines, Consumer Health Care (CHC), Animal Health, Genzyme, and Other Innovative Products. The Pharmaceuticals segment covers research, development, production and marketing of medicines, including activities acquired with Genzyme. Sanofi's pharmaceuticals portfolio consists of flagship products, plus prescription medicines, generic medicines, and consumer health products. This segment also includes all associates and joint ventures whose activities are related to pharmaceuticals, in particular the entities majority owned by BMS. The Vaccines segment is wholly dedicated to vaccines, including research, development, production and marketing. This segment includes Sanofi Pasteur MSD joint venture with Merck & Co., Inc. in Europe. The Animal Health segment comprises the research, development, production and marketing activities of Merial, which offers medicines and vaccines for a wide variety of animal species. Its competitors include Novo Nordisk, Merck, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Shire, Pfizer, Biogen Idec, Teva and Merck Serono, Bayer, Roche, Johnson & Johnson, AstraZeneca, Boehringer-Ingelheim, Fresenius Medical Care, among others. The Company's products and manufacturing facilities are subject to significant government regulations and approvals.
Emily Field analyst at Barclays reiterates coverage on Sanofi (SNYNF) stock in the energy sector with a Buy rating and has set SNYNF's stock price target at $ 123.76.
TipRanks.com reports that Sanofi currently has 14 analysts offering 12-month price targets on SNYNF and the consensus is a Moderate Buy rating with an average stock price target of $114.22. The most recent SNYNF stock price we have is $107.05 and we are not making any SNYNF forecasts at this time.
In addition, Barchart.com has a Strong buy rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on SNYNF. greenstockmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on SNYNF, please click here >>
The editors at greenstockmovers.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
GreenStockMovers.com keeps investors informed of the top moving stocks within the energy sector. We provide investors with timely information regarding top moving stocks in the green energy sector sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to GreenStockMovers.com
==============================================================================
